Standout Papers

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Pr... 2004 2026 2011 2018 2.8k
  1. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer (2004)
    Daniel P. Petrylak, Catherine M. Tangen et al. New England Journal of Medicine
  2. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (2017)
    Joaquim Bellmunt, Ronald de Wit et al. New England Journal of Medicine
  3. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (2014)
    Thomas Powles, Joseph P. Eder et al. Nature
  4. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer (2019)
    Andrew J. Armstrong, Russell Z. Szmulewitz et al. Journal of Clinical Oncology
  5. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma (2021)
    Thomas Powles, Jonathan E. Rosenberg et al. New England Journal of Medicine
  6. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy (1996)
    George L. Wright, B. Mayer Grob et al. Urology
  7. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy (2019)
    Jonathan E. Rosenberg, Peter H. O’Donnell et al. Journal of Clinical Oncology
  8. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors (2021)
    Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology
  9. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up (2019)
    Yves Fradet, Joaquim Bellmunt et al. Annals of Oncology
  10. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma (2020)
    Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology
  11. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial (2021)
    Evan Y. Yu, Daniel P. Petrylak et al. The Lancet Oncology
  12. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer (2022)
    Andrew J. Armstrong, Arun Azad et al. Journal of Clinical Oncology
  13. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer (2022)
    Christopher Hoimes, Thomas W. Flaig et al. Journal of Clinical Oncology
  14. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). (2022)
    Xīn Gào, Howard A. Burris et al. Journal of Clinical Oncology
  15. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma (2023)
    Jonathan E. Rosenberg, Thomas Powles et al. Annals of Oncology

Immediate Impact

10 by Nobel laureates 10 from Science/Nature 93 standout
Sub-graph 1 of 17

Citing Papers

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
2023 Standout
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
2023 Standout
13 intermediate papers

Works of Daniel P. Petrylak being referenced

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
2021 Standout
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
2016
and 11 more

Author Peers

Author Last Decade Papers Cites
Daniel P. Petrylak 10428 10847 7214 521 22.4k
Christopher J. Logothetis 9469 7820 3858 448 20.4k
Ronald de Wit 13147 10045 8911 371 25.7k
Joaquim Bellmunt 11529 13233 15103 637 29.5k
Joel Picus 8932 9106 2465 223 17.7k
Cora N. Sternberg 20500 11771 10258 578 33.5k
Walter M. Stadler 13822 9239 4293 466 26.3k
Derek Raghavan 6935 6431 8730 292 18.7k
Robert S. Benjamin 13510 11394 4110 474 24.7k
Roger B. Cohen 5780 9018 3309 320 17.1k
Filippo de Braud 8522 17473 5482 749 26.0k

All Works

Loading papers...

Rankless by CCL
2026